Menu
Back to User profile » Dr M.S. Zastrozhin
Papers published by Dr M.S. Zastrozhin:
Pharmacogenetics of alcohol addiction: current perspectives
Zastrozhin MS, Skryabin VY, Miroshkin SS, Bryun EA, Sychev DA
The Application of Clinical Genetics 2019, 12:131-140
Published Date: 11 July 2019
Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder
Zastrozhin MS, Grishina EA, Denisenko NP, Skryabin VY, Markov DD, Savchenko LM, Bryun EA, Sychev DA
Pharmacogenomics and Personalized Medicine 2018, 11:113-119
Published Date: 29 June 2018
The influence of CYP3A5 polymorphisms on haloperidol treatment in patients with alcohol addiction
Zastrozhin MS, Grishina EA, Ryzhikova KA, Smirnov VV, Savchenko LM, Bryun EA, Sychev DA
Pharmacogenomics and Personalized Medicine 2018, 11:1-5
Published Date: 28 December 2017
Pharmacodynamic genetic polymorphisms affect adverse drug reactions of haloperidol in patients with alcohol-use disorder
Zastrozhin MS, Brodyansky VM, Skryabin VY, Grishina EA, Ivashchenko DV, Ryzhikova KA, Savchenko LM, Kibitov AO, Bryun EA, Sychev DA
Pharmacogenomics and Personalized Medicine 2017, 10:209-215
Published Date: 7 July 2017
The correlation between CYP2D6 isoenzyme activity and haloperidol efficacy and safety profile in patients with alcohol addiction during the exacerbation of the addiction
Sychev DA, Zastrozhin MS, Smirnov VV, Grishina EA, Savchenko LM, Bryun EA
Pharmacogenomics and Personalized Medicine 2016, 9:89-95
Published Date: 14 September 2016